Advances in epidermal growth factor receptor specific immunotherapy: lessons to be learned from armed antibodies

Area of Science:

• Oncology and Immunology
• Molecular Biology
• Drug Development

Background:

• Epidermal growth factor receptor (EGFR) is a key target in oncology due to its overexpression in solid tumors and role in cancer progression.
• EGFR's involvement in cell survival, proliferation, metastasis, and angiogenesis makes it crucial for cancer aggressiveness.
• Early anti-EGFR monoclonal antibodies (mAbs) faced limitations like immune reactions and poor tumor penetration.

Purpose of the Study:

• To review advancements in EGFR-targeting immunoconjugates for cancer immunotherapy.
• To highlight the evolution from early mAbs to antibody-drug conjugates (ADCs) and immunotoxins (ITs).
• To discuss refined strategies including deimmunization and recombinant technologies.

Main Methods:

• Review of scientific literature on EGFR-targeting immunoconjugates.
• Analysis of developments in antibody-drug conjugates (ADCs) and immunotoxins (ITs).
• Discussion of deimmunization strategies and recombinant antibody technologies.

Main Results:

• Development of antibody-drug conjugates (ADCs) and immunotoxins (ITs) by modifying anti-EGFR mAbs.
• Refinement of immunotoxins (ITs) through deimmunization and use of human enzymes.
• Creation of fully recombinant antibody-drug conjugates (ADCs).

Conclusions:

• EGFR-targeting immunoconjugates, including ITs and recombinant ADCs, represent significant progress in cancer immunotherapy.
• These advanced therapies offer improved strategies for targeted cancer treatment.
• Further developments in EGFR-targeting immunoconjugates hold promise for future cancer immunotherapy.